AMLM26- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial - The Master Protocol
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Azacitidine (Primary) ; Cedazuridine/decitabine (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Revumenib (Primary) ; Sabatolimab (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms INTERCEPT
- 07 Dec 2024 Initial result (as of the latest data cutoff, n=14) presented in the Syndax Pharmaceuticals Media Release.
- 07 Dec 2024 According to a Syndax Pharmaceuticals media release, Initial result data from this trial were presented at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024.
- 05 Nov 2024 According to a Syndax Pharmaceuticals media release, Preliminary results from the first eight mNPM1 patients treated with revumenib will be presented at the upcoming 66th ASH Annual Meeting.